Robert Clarke (Kinaset)

Ki­naset launch­es with $40M and a JAK in­hibitor from Vec­tura's old pipeline

Ki­naset Ther­a­peu­tics is join­ing the search for a bet­ter se­vere asth­ma treat­ment, pick­ing up where Vec­tura left off when it de­cid­ed to clear house last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.